以跨专业ICU团队实施的家庭支持干预对死亡或严重功能损害高风险ICU患者住院费用及再入院的影响
本研究为PARTNER试验的多中心阶梯楔形整群随机对照试验,评估跨专业ICU团队提供的家庭支持干预对死亡或严重功能损害高风险重症患者住院费用及出院后资源利用的影响。结果显示,与常规治疗相比,干预组可控总费用(几何均值:26,529美元 vs 32,105美元;对数线性系数:-0.30;95%CI -0.49, -0.11)和直接可变费用(3,912美元 vs 6,034美元;-0.33;95%CI -0.56, -0.10)显著降低;死亡者费用降低幅度(20,304美元 vs 26,610美元;-0.66;95%CI -1.01, -0.31)大于存活者(31,353美元 vs 35,015美元;-0.15;95%CI -0.35, 0.05)。干预组再入院至急性护理医院的比例较低(34.9% vs 45.1%;0.66;95%CI 0.56, 0.77),再入院至专业护理机构的比例也较低(25.3% vs 31.6%;0.63;95%CI 0.47, 0.84)。
要点
- 跨专业ICU团队家庭支持干预组可控总费用几何均值26,529美元 vs 常规护理组32,105美元(对数线性系数-0.30;95%CI -0.49, -0.11)。
- 干预组直接可变费用3,912美元 vs 常规护理组6,034美元(系数-0.33;95%CI -0.56, -0.10)。
- 死亡者费用降低幅度大于存活者:死亡者20,304美元 vs 26,610美元(系数-0.66;95%CI -1.01, -0.31);存活者31,353美元 vs 35,015美元(系数-0.15;95%CI -0.35, 0.05)。
- 干预组再入院至急性护理医院比例34.9% vs 45.1%(0.66;95%CI 0.56, 0.77),再入院至专业护理机构比例25.3% vs 31.6%(0.63;95%CI 0.47, 0.84)。
- 干预组6个月随访期内再入院率显著降低。
适用人群与场景
- 死亡或严重功能损害高风险的危重症患者。
处置流程与药物剂量
- 由跨专业ICU团队提供家庭支持干预(PARTNER干预)。
研究设计与关键结果
- 研究设计:PARTNER试验,多中心、阶梯楔形、整群随机对照试验。
- 干预:跨专业ICU团队提供的家庭支持干预;对照:常规护理。
- 主要终点:指标住院费用(可控总费用和直接可变费用)及出院后6个月内资源利用。
- 可控总费用:干预组几何均值26,529美元 vs 常规护理组32,105美元;对数线性系数-0.30;95%CI -0.49, -0.11。
- 直接可变费用:干预组3,912美元 vs 常规护理组6,034美元;系数-0.33;95%CI -0.56, -0.10。
- 死亡者费用:干预组20,304美元 vs 常规护理组26,610美元;系数-0.66;95%CI -1.01, -0.31。
- 存活者费用:干预组31,353美元 vs 常规护理组35,015美元;系数-0.15;95%CI -0.35, 0.05。
- 再入院至急性护理医院比例:干预组34.9% vs 常规护理组45.1%;0.66;95%CI 0.56, 0.77。
证据类型、等级与局限
- 证据类型:多中心、阶梯楔形、整群随机对照试验。
- 试验注册号:NCT01844492。
- 局限:原文未报告局限性。
对床旁实践的改变
- 由跨专业ICU团队提供家庭支持干预可降低死亡或严重功能损害高风险患者的指标住院费用和再入院率。
指南或共识出处
- PARTNER试验(NCT01844492)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with advanced critical illness often receive more intensive treatment than they would choose for themselves, which contributes to high health care costs near the end of life. The purpose of this study was to determine whether a family support intervention delivered by the interprofessional ICU team decreases hospitalization costs and hospital readmissions among critically ill patients at high risk of death or severe functional impairment.
RESULTS: We examined index hospitalization costs as well as post-discharge utilization of acute care hospitals, rehabilitation and skilled nursing facilities, and hospice services for the PARTNER trial, a multicenter, stepped-wedge, cluster randomized trial of an interprofessional ICU family support intervention. We determined patients' total controllable and direct variable costs using a computerized accounting system. We determined post-discharge resource utilization (as defined above) by structured telephone interview at 6-month follow-up. We used multiple variable regression modelling to compare outcomes between groups. Compared to usual care, the PARTNER intervention resulted in significantly lower total controllable costs (geometric mean: $26,529 vs $32,105; log-linear coefficient: - 0.30; 95% CI - 0.49, - 0.11) and direct variable costs ($3912 vs $6034; - 0.33; 95% CI - 0.56, - 0.10). A larger cost reduction occurred for decedents ($20,304 vs. $26,610; - 0.66; 95% CI - 1.01, - 0.31) compared to survivors ($31,353 vs. $35,015; - 0.15; 95% CI - 0.35,0.05). A lower proportion in the intervention arm were re-admitted to an acute care hospital (34.9% vs 45.1%; 0.66; 95% CI 0.56, 0.77) or skilled nursing facility (25.3% vs 31.6%; 0.63; 95% CI 0.47, 0.84).
CONCLUSIONS: A family support intervention delivered by the interprofessional ICU team significantly decreased index hospitalization costs and readmission rates over 6-month follow-up. Trial registration Trial registration number: NCT01844492.
参考来源
- Andersen SK, Chang CH, Arnold RM, et al. Impact of a family support intervention on hospitalization costs and hospital readmissions among ICU patients at high risk of death or severe functional impairment. Ann Intensive Care. 2024. PMID: 38954149. doi:10.1186/s13613-024-01344-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。